Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | MARS1 | P56192 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23593323 | 0.86 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19RAB9ACNR1 | |
| SCHEMBL23593328 | 0.86 | RHOC (0.45) | CNR1POLB | |
| SCHEMBL24118262 | 0.83 | RAB9A (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19RAB9A | |
| SCHEMBL24118254 | 0.76 | FPR2 (0.48) | CYP1A2CYP2C19RAB9ACNR1POLB | |
| SCHEMBL24118338 | 0.76 | GCGR (0.46) | IDO1CNR1POLBKLK7GRIK1 | |
| SCHEMBL24118279 | 0.76 | MEN1 (0.59) | CYP1A2CYP3A4CYP2C19RAB9ASLC2A1 | |
| SCHEMBL23593322 | 0.76 | POLB (0.48) | CYP1A2CYP2C19RAB9APOLBKLK7 | |
| SCHEMBL24118326 | 0.75 | GCG (0.49) | RAB9APOLBKLK7GRIK1 | |
| SCHEMBL24118405 | 0.74 | KMT2A (0.44) | RAB9AIDO1CNR1POLB | |
| SCHEMBL24118062 | 0.74 | IDO1 (0.54) | IDO1POLBKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210198190-A1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198190-A1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | CYP1A2 147/4885CYP3A4 905/4885CYP2D6 236/4885 |
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | CYP1A2 120/4885CYP3A4 842/4885CYP2D6 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.